Biocryst Pharmaceuticals (BCRX) Current Assets (2010 - 2026)

Biocryst Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $373.6 million for Q1 2026.

• Quarterly Current Assets fell 8.87% year-over-year to $373.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.6 million (down 8.87% YoY) and the FY2025 annual result came in at $404.3 million, down 4.18% from the prior year.
• Current Assets was $373.6 million for Q1 2026 at Biocryst Pharmaceuticals, down from $404.3 million in the prior quarter.
• Across five years, Current Assets topped out at $516.5 million in Q4 2022 and bottomed at $355.7 million in Q3 2025.
• A 5-year average of $449.1 million and a median of $447.1 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets soared 101.39% — and 2024, when it fell 28.88%.
• Biocryst Pharmaceuticals' Current Assets stood at $516.5 million in 2022, then declined by 3.98% to $496.0 million in 2023, then declined by 14.92% to $422.0 million in 2024, then decreased by 4.18% to $404.3 million in 2025, then declined by 7.6% to $373.6 million in 2026.
• Business Quant data shows BCRX's Current Assets at $373.6 million in Q1 2026, $404.3 million in Q4 2025, and $355.7 million in Q3 2025.